These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 19174554

  • 1. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.
    Luster TA, Carrell JA, McCormick K, Sun D, Humphreys R.
    Mol Cancer Ther; 2009 Feb; 8(2):292-302. PubMed ID: 19174554
    [Abstract] [Full Text] [Related]

  • 2. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
    Voortman J, Resende TP, Abou El Hassan MA, Giaccone G, Kruyt FA.
    Mol Cancer Ther; 2007 Jul; 6(7):2103-12. PubMed ID: 17620439
    [Abstract] [Full Text] [Related]

  • 3. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.
    Belyanskaya LL, Marti TM, Hopkins-Donaldson S, Kurtz S, Felley-Bosco E, Stahel RA.
    Mol Cancer; 2007 Oct 22; 6():66. PubMed ID: 17953743
    [Abstract] [Full Text] [Related]

  • 4. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.
    Smith MR, Jin F, Joshi I.
    Clin Cancer Res; 2007 Sep 15; 13(18 Pt 2):5528s-5534s. PubMed ID: 17875785
    [Abstract] [Full Text] [Related]

  • 5. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.
    Seki N, Toh U, Sayers TJ, Fujii T, Miyagi M, Akagi Y, Kusukawa J, Kage M, Shirouzu K, Yamana H.
    Mol Cancer Ther; 2010 Jun 15; 9(6):1842-51. PubMed ID: 20515944
    [Abstract] [Full Text] [Related]

  • 6. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
    Brooks AD, Jacobsen KM, Li W, Shanker A, Sayers TJ.
    Mol Cancer Res; 2010 May 15; 8(5):729-38. PubMed ID: 20442297
    [Abstract] [Full Text] [Related]

  • 7. TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors.
    Stadel D, Mohr A, Ref C, MacFarlane M, Zhou S, Humphreys R, Bachem M, Cohen G, Möller P, Zwacka RM, Debatin KM, Fulda S.
    Clin Cancer Res; 2010 Dec 01; 16(23):5734-49. PubMed ID: 20940278
    [Abstract] [Full Text] [Related]

  • 8. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner.
    Wu XX, Kakehi Y.
    Clin Cancer Res; 2009 Mar 15; 15(6):2039-47. PubMed ID: 19276256
    [Abstract] [Full Text] [Related]

  • 9. Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma.
    Engesæter B, Engebraaten O, Flørenes VA, Mælandsmo GM.
    PLoS One; 2012 Mar 15; 7(9):e45492. PubMed ID: 23029050
    [Abstract] [Full Text] [Related]

  • 10. Primary ovarian cancer cells are sensitive to the proaptotic effects of proteasome inhibitors.
    Pasquini L, Petronelli A, Petrucci E, Saulle E, Mariani G, Scambia G, Benedetti-Panici P, Greggi S, Cognetti F, Testa U.
    Int J Oncol; 2010 Mar 15; 36(3):707-13. PubMed ID: 20126991
    [Abstract] [Full Text] [Related]

  • 11. Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer.
    Malin D, Chen F, Schiller C, Koblinski J, Cryns VL.
    Clin Cancer Res; 2011 Aug 01; 17(15):5005-15. PubMed ID: 21653692
    [Abstract] [Full Text] [Related]

  • 12. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
    Lashinger LM, Zhu K, Williams SA, Shrader M, Dinney CP, McConkey DJ.
    Cancer Res; 2005 Jun 01; 65(11):4902-8. PubMed ID: 15930312
    [Abstract] [Full Text] [Related]

  • 13. Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.
    Bullenkamp J, Raulf N, Ayaz B, Walczak H, Kulms D, Odell E, Thavaraj S, Tavassoli M.
    Cell Death Dis; 2014 Oct 23; 5(10):e1489. PubMed ID: 25341043
    [Abstract] [Full Text] [Related]

  • 14. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, Sun SY.
    Cancer Res; 2007 May 15; 67(10):4981-8. PubMed ID: 17510429
    [Abstract] [Full Text] [Related]

  • 15. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
    Shanker A, Brooks AD, Tristan CA, Wine JW, Elliott PJ, Yagita H, Takeda K, Smyth MJ, Murphy WJ, Sayers TJ.
    J Natl Cancer Inst; 2008 May 07; 100(9):649-62. PubMed ID: 18445820
    [Abstract] [Full Text] [Related]

  • 16. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.
    Unterkircher T, Cristofanon S, Vellanki SH, Nonnenmacher L, Karpel-Massler G, Wirtz CR, Debatin KM, Fulda S.
    Clin Cancer Res; 2011 Jun 15; 17(12):4019-30. PubMed ID: 21525171
    [Abstract] [Full Text] [Related]

  • 17. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
    Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4556-64. PubMed ID: 17671142
    [Abstract] [Full Text] [Related]

  • 18. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
    Kabore AF, Sun J, Hu X, McCrea K, Johnston JB, Gibson SB.
    Apoptosis; 2006 Jul 01; 11(7):1175-93. PubMed ID: 16699949
    [Abstract] [Full Text] [Related]

  • 19. Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression.
    Wu XX, Jin XH, Zeng Y, El Hamed AM, Kakehi Y.
    Cancer Sci; 2007 Dec 01; 98(12):1969-76. PubMed ID: 17922852
    [Abstract] [Full Text] [Related]

  • 20. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.
    Saulle E, Petronelli A, Pasquini L, Petrucci E, Mariani G, Biffoni M, Ferretti G, Scambia G, Benedetti-Panici P, Cognetti F, Humphreys R, Peschle C, Testa U.
    Apoptosis; 2007 Apr 01; 12(4):635-55. PubMed ID: 17252198
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.